ANT-GROUP
13.6.2024 06:45:32 CEST | Business Wire | Press release
Ant Group (or “the Company”) today released its 2023 Sustainability Report, showcasing the Company’s significant progress since the introduction of its ESG strategy in 2022 and demonstrating its commitment to transparency and to its sustainable business practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612743798/en/
Technological Innovation (Graphic: Business Wire)
The report highlights noteworthy advancements across key areas, underpinned by four core pillars: Technological Innovation, Digital Inclusion, Green and Low-Carbon Development, and Open Ecosystem.
“Looking ahead, we are constantly reflecting on how to stay true to our original aspirations in this era of rapid change, continuously bringing about more small yet beautiful changes to the world,” said Eric Jing, Chairman & CEO of Ant Group. “Since our journey started from Alipay’s inception in 2004, technology-driven innovation has always been the fundamental force propelling our growth. It will play an even greater role in shaping our future.”
Technological Innovation
To drive innovation for consumers, small and micro-sized enterprises (SMEs) and partners, Ant Group has increased its investment in technology R&D for three consecutive years, reaching a record high of RMB 21.19 billion yuan (~ 2.92 billion USD) in 2023. Ant Group’s BaiLing Foundation Model, which was approved to serve the Chinese public in 2023, has been powering AI assistants that make it easier for users to access various life services on the Alipay platform, from smart life assistant, to smart healthcare manager and smart financial manager.
Digital Inclusion
By leveraging digital payment and finance innovation, Ant Group, together with its associate MYbank, have served more than 87 million SMEs as of 2023.
On the Alipay platform, thousands of Independent Software Vendors (ISVs) have developed more than 700 digital solutions for 4.27 million merchants, enabling them to seize more business opportunities through digital operations. In 2023, the annual transaction volume of merchant operated Alipay mini-programs grew by 68% year-on-year.
Green and Low-Carbon Development
By the end of 2023, Ant Group had achieved operation-wide carbon neutrality for three consecutive years, with a 43.19% reduction in absolute Scope 1 & 2 emissions compared to the 2020 baseline year. In accordance with standards such as the "Greenhouse Gas Protocol: Corporate Value Chain (Scope 3) Accounting and Reporting Standards" and the "Global Financial Industry Greenhouse Gas Accounting and Reporting Standards," Ant Group conducted the Company’s first comprehensive accounting for Scope 3 carbon emissions in 2023, covering 11 categories related to activities along Ant Group's value chain, which provides a scientific basis for further emission reduction initiatives.
Since its launch in 2016, Alipay Ant Forest has encouraged more than 690 million users to make everyday low-carbon choices. As a result, 475 million trees have been planted by local partners with financial support from the Company.
Open Ecosystem
To better connect travelers with merchants and facilitate cross-border commerce, more than 25 leading e-wallets and banking apps have adopted Alipay+, a suite of cross-border digital payment and digitalization technology solutions. Alipay+ enables their users to pay and travel like locals, bringing international businesses to over 88 million merchants worldwide. In addition, with its one World Account, WorldFirst has served one million SME traders to pay, connect, and manage money globally.
The 10x1000 Tech for Inclusion program has provided exchange and learning opportunities for 6,243 certified learners from over 100 countries and regions, of whom nearly half are women participants.
Ant Group, after establishing 19 sustainability issues with 3-year OKRs (Objectives and Key Results) and plans in 2022, has upgraded its governance and incentive system in line with global best practices. This includes linking senior management’s remuneration to the Company’s risk management and sustainability performance metrics.
In 2023, Ant Group used relevant Sustainability Accounting Standards Board(SASB) industry standards as a guiding reference for its sustainability reporting for the first time. Ant Group also bolstered its climate-related disclosures with reference to the International Sustainability Standards Board (ISSB) requirements, including detailing how its executives and senior management tackle climate-related decisions as well as the establishment of an early warning platform to monitor extreme weather's impact on business operations.
Note: All figures are as of December 31, 2023 unless otherwise specified. The 2023 Sustainability Report is available in Chinese. The English-language version will be available on Ant Group’s official website soon.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612743798/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom